



# Do you have a Humira biosimilar strategy?

Humira likely ranks #1 or #2 in drug spend in your health plan today.

With biosimilars finally emerging, there is opportunity to reduce costs while achieving equivalent health outcomes.



## Timeline

The first biosimilar is expected to hit the market in January 2023 with 6 months exclusivity.<sup>[1]</sup>

## Numbers

There are 7 FDA-approved biosimilars today and more in the pipeline. According to the FDA, there could be as many as 11 biosimilars competing for market share by mid-2023.<sup>[2]</sup>



## What It Means for You

Biosimilars have been shown to be **15%–35% lower in cost** than the reference product. Plans should be developed now in preparation for product launches, competition, and other market forces.

## Create Your Biosimilar Strategy!

Get in touch with AArete's Pharmacy expert:



Leslie Lotano-Saba, RPh, MS,  
VP Pharmacy Solutions | AArete  
[LLotano-Saba@AArete.com](mailto:LLotano-Saba@AArete.com)